Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

HLA-DRB1, IRF5, and CD28 gene polymorphisms in Egyptian patients with rheumatoid arthritis: susceptibility and disease activity

Abstract

This study was established to assess the effects of IRF5 rs10488631 and CD28 rs1980422 single-nucleotide polymorphisms (SNPs) and HLA-DRB1 shared epitope (SE) allele on the prognosis and disease activity of rheumatoid arthritis (RA) patients. A total of 150 RA patients and 150 healthy controls were genotyped for the selected SNPs by real-time PCR. HLA-DRB1 SE was determined using LAB Type SSO Class II DRB1 typing. Our results suggest that HLA-DRB1, CD28, and IRF5 significantly discriminated (p < 0.001) RA patients and healthy controls (OR of single HLA-DRB1 SE allele = 2.431, CI = 1.467–4.027, OR of two SE alleles = 11.152, CI = 2.479–50.159), (OR of CD28 risk allele C = 2.794, 95% CI = 1.973–3.956) and (OR of IRF5 risk allele C = 4.925, CI = 3.26–7.439). Rheumatoid factor (RF) seropositivity was associated with HLA-DRB1 SE (p < 0.001) and IRF5 risk allele (p < 0.001). ACPA was significantly associated only with IRF5 risk allele (p < 0.001). A better response to methotrexate therapy was found in HLA-DRB1 SE non-carriers, and CD28 TT patients. This study demonstrated associations of HLA-DRB1 SE, CD28, and IRF5 with the risk of RA. HLA-DRB1 SE and CD28 rs1980422 can be used as predictors of methotrexate therapy response.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Effect of different genotypes on therapy response.

References

  1. 1.

    Imanaka T, Shichikawa K, Inoue K, Shimaoka Y, Takenaka Y, Wakitani S. Increase in age at onset of rheumatoid arthritis in Japan over a 30 year period. Ann Rheum Dis. 1997;56:313–6.

    CAS  Article  Google Scholar 

  2. 2.

    Lin L, Chen Y, Xiao Z, Huang S, Yang Z. The association of HLA-DRB1 alleles with rheumatoid arthritis in the Chinese Shantou population: a follow-up study. Biochem Cell Biol. 2007;85:227–38.

    CAS  Article  Google Scholar 

  3. 3.

    Oka S, Furukawa H, Shimada K, Hashimoto A, Komiya A, Tsunoda S, et al. Association of HLA-DRB1 genotype with younger age onset and elder age onset rheumatoid arthritis in Japanese populations. Medicine. 2019;98:e18218.

    CAS  Article  Google Scholar 

  4. 4.

    Raslan HM, Attia HR, Hamed Ibrahim M, Mahmoud Hassan E, Salama, II, Ismail S, et al. Association of anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes with HLA-DRB1 shared epitope alleles in Egyptian rheumatoid arthritis patients. Int J Rheum Dis. 2020;23:647–53.

  5. 5.

    Luterek-Puszyńska K, Malinowski D, Paradowska-Gorycka A, Safranow K, Pawlik A. CD28, CTLA-4 and CCL5 gene polymorphisms in patients with rheumatoid arthritis. Clin Rheumatol. 2017;36:1129–35.

    Article  Google Scholar 

  6. 6.

    Crow MK. Costimulatory molecules and T-cell-B-cell interactions. Rheum Dis Clin North Am. 2004;30:175–91.

    Article  Google Scholar 

  7. 7.

    Vernerova L, Spoutil F, Vlcek M, Krskova K, Penesova A, Meskova M, et al. A combination of CD28 (rs1980422) and IRF5 (rs10488631) polymorphisms is associated with seropositivity in rheumatoid arthritis: a case control study. PLoS ONE. 2016;11:e0153316.

    Article  Google Scholar 

  8. 8.

    Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70:2029–36.

    CAS  Article  Google Scholar 

  9. 9.

    Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet. 2006;38:550–5.

    CAS  Article  Google Scholar 

  10. 10.

    García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, Llorca J, González-Juanatey C, et al. Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis. Arthritis Res Ther. 2014;16:R146.

    Article  Google Scholar 

  11. 11.

    Wang C, Kokkonen H, Sandling JK, Johansson M, Seddighzadeh M, Padyukov L, et al. Preferential association of interferon regulatory factor 5 gene variants with seronegative rheumatoid arthritis in 2 Swedish case-control studies. J Rheumatol. 2011;38:2130–2.

    CAS  Article  Google Scholar 

  12. 12.

    Juge PA, Gazal S, Constantin A, Mariette X, Combe B, Tebib J, et al. Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD Open. 2017;3:e000448.

    Article  Google Scholar 

  13. 13.

    van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007;66:1008–14.

    Article  Google Scholar 

  14. 14.

    Prasad P, Kumar A, Gupta R, Juyal RC, Thelma BK. Caucasian and Asian specific rheumatoid arthritis risk loci reveal limited replication and apparent allelic heterogeneity in north Indians. PLoS ONE. 2012;7:e31584.

    CAS  Article  Google Scholar 

  15. 15.

    Kim YO, Kim HJ, Kim SK, Chung JH, Hong SJ. Association of the CD28/CTLA4/ICOS polymorphisms with susceptibility to rheumatoid arthritis. Clin Chem Lab Med. 2010;48:345–53.

    CAS  PubMed  Google Scholar 

  16. 16.

    Ledezma-Lozano IY, Padilla-Martínez JJ, Leyva-Torres SD, Parra-Rojas I, Ramírez-Dueñas MG, Pereira-Suárez AL, et al. Association of CD28 IVS3 +17T/C polymorphism with soluble CD28 in rheumatoid arthritis. Dis Markers. 2011;30:25–9.

    CAS  Article  Google Scholar 

  17. 17.

    Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet. 2009;41:1313–8.

    CAS  Article  Google Scholar 

  18. 18.

    Ding B, Padyukov L, Lundström E, Seielstad M, Plenge RM, Oksenberg JR, et al. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum. 2009;60:30–8.

    CAS  Article  Google Scholar 

  19. 19.

    Viatte S, Barton A. Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. Semin Immunopathol. 2017;39:395–408.

    CAS  Article  Google Scholar 

  20. 20.

    Imboden JB, Hellmann DB, Stone JH. Current diagnosis and treatment. 2013.

  21. 21.

    Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.

    CAS  Article  Google Scholar 

  22. 22.

    Salaffi F, Ciapetti A. Clinical disease activity assessments in rheumatoid arthritis. Int J Clin Rheumatol. 2013;8:1758–4272.

    Article  Google Scholar 

Download references

Acknowledgements

Language editing was done by Enago Editing Services.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Nora M. Said.

Ethics declarations

Conflict of interest

The authors declare no competing interests

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Said, N.M., Ezzeldin, N., Said, D. et al. HLA-DRB1, IRF5, and CD28 gene polymorphisms in Egyptian patients with rheumatoid arthritis: susceptibility and disease activity. Genes Immun 22, 93–100 (2021). https://doi.org/10.1038/s41435-021-00134-8

Download citation

Search

Quick links